Eisai Alzheimer's Drug Discovery Foundation, Pharma Firms Form Biobank Alliance Roche, Shionogi, Janssen Pharmaceuticals, and Eisai will provide the charity with specimens from Alzheimer's disease patients who participated in clinical studies. PGDx, Eisai to Develop Next-Generation Sequencing Biomarker Assay The group will create a kitted next-generation sequencing tool that will help researchers and biopharma firms conduct biomarker discovery work on patient blood samples. AmoyDx, Eisai Form CDx Development Alliance Tokyo-based Eisai develops drugs primarily for the neurology and oncology markets, including treatments for Parkinson's disease and breast cancer. Bristol-Myers Squibb, H3 Biomedicine Form Cancer Immunotherapy Alliance H3, a subsidiary of Japanese drugmaker Eisai, is developing personalized cancer treatments targeting genomic alterations, including aberrant RNA splicing. Cancer Genetics Signs Biomarker Services Deal with H3 Biomedicine Cancer Genetics will provide the services to support H3's development of H3B-8800, a Phase I small molecule-based blood cancer drug candidate. Feb 16, 2016 Eisai, Sysmex to Develop Dx, CDx for Dementia Dec 17, 2014 Oncodesign, Eisai Reach Deal to Assess Eribulin Apr 3, 2014 Eisai Researchers Developing microRNA-based Diagnostic for Alzheimer's Disease Premium Jul 11, 2013 Seegene and Eisai's Eidia Partner on MDx Tests in Japan Premium Jul 1, 2013 Seegene Signs Japan Marketing Deal with Eidia Jan 10, 2013 Epizyme Taps Roche to Develop Cobas 4800 CDx for Epizyme/Eisai Lymphoma Drug Candidate Premium Jan 7, 2013 Epizyme, Eisai, Roche Partner to Develop CDx for Investigational Lymphoma Treatment Oct 10, 2012 Eisai to Dissolve Dx R&D Subsidiary as It Focuses on Personalized Medicine Oct 9, 2012 Foundation Medicine, Eisai Ink Personalized Med Alliance May 16, 2012 With Celgene Partnership Epizyme Hopes to Accelerate Personalized Epigenetic Drug Development Premium Apr 6, 2012 IP Update: Recent Patents Awarded to Thermo Fisher Scientific; Eisai; and More Premium Jul 1, 2011 Evotec to Use PhosphoScout Platform in Oncology Biomarker Alliance with Roche Premium May 4, 2011 Supreme Court Case on Script Data Sale Presents 'Gray Area' for PBM Personalized Rx Efforts Premium Apr 6, 2011 AACR Presentations Highlight BATTLE Trial as New Model for Biomarker-Based Drug Studies Premium Apr 1, 2011 Proteome Sciences Signs Contract with Takeda for Protein Biomarker Research Premium Feb 4, 2011 Proteome Sciences Inks Deal with Eisai for First Commercial Use of Alzheimer's Biomarker Panel Premium Feb 2, 2011 Eisai Invests in Development of Personalized Cancer Rx via Stake in Biotech Startup Premium Jan 31, 2011 Proteome Sciences Providing Biomarker Services to Eisai Jan 28, 2011 Eisai Creates US Subsidiary H3 Biomedicine with up to $200M Nov 18, 2010 Eisai Gains Access to Forma's Drug Screening Technology Load More Breaking News SomaLogic Inks Partnership for Testing in UAE, Firm's Q2 Revenues Down 29 Percent Phenotype Ties to Rare Variants Systematically Unearthed in UK Biobank Exomes Ginkgo Bioworks, XpresCheck Receive $16M CDC Contract for SARS-CoV-2 Surveillance in US Airports Personalis, BC Cancer Partner on Study of ctDNA MRD Tests for Colorectal, Pancreatic Cancers Verogen, Gene by Gene Strike Forensic Genetics Alliance The Scan Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels. Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing. BMI-Related Variants Show Age-Related Stability in UK Biobank Participants Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics. Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.